{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:30:35Z","timestamp":1791851435181,"version":"4.3.4"},"reference-count":50,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Aim: Fibrates have proven efficacy in cardiovascular risk reduction and are commonly used, in addition to statins, to control hypertriglyceridaemia. Their use is often limited due to reduction in glomerular filtration rate at treatment initiation. However, recent studies suggest benign changes in kidney function and improvement of proteinuria, an established early marker of microvascular disease and kidney disease progression. We summarize the evidence from existing trials and provide a summary of effects of fibrates, alone or in combination, on kidney disease progression and proteinuria. Methods and Results: Systematic review and meta-analysis of randomized, controlled trials (PROSPERO CRD42020187764). Out of 12,243 potentially eligible studies, 29 were included in qualitative and quantitative analysis, with a total of 20,176 patients. Mean creatinine increased by 1.05 (95% CI (0.63 to 1.46)) units in patients receiving fibrates vs. comparator, and this was similar in all other subgroups. eGFR showed a bigger decrease in the fibrates arm (SMD \u22121.99; 95% CI (\u22123.49 to \u22120.48)) when all studies were pooled together. Notably, short-term serum creatinine and eGFR changes remained constant in the long-term. Pooled estimates show that fibrates improve albuminuria progression, RR 0.86; 95% CI (0.76 to 0.98); albuminuria regression, RR 1.19; 95% CI (1.08 to 1.310). Conclusions: Fibrates improve albuminuria in patients with and without diabetes when used to treat hyperlipidaemia. The modest creatinine increase should not be a limiting factor for fibrate initiation in people with preserved renal function or mild CKD. The long-term effects on kidney disease progression warrant further study.<\/jats:p>","DOI":"10.3390\/jcm11030768","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T08:20:29Z","timestamp":1643617229000},"page":"768","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The Effect of Fibrates on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis of Randomised Studies"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-1068","authenticated-orcid":false,"given":"Alexandros","family":"Hadjivasilis","sequence":"first","affiliation":[{"name":"Cardiovascular Epidemiology and Genetics Research Lab, Cyprus International Institute for Environmental and Public Health, Cyprus University of Technology, Limassol 3036, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Kouis","sequence":"additional","affiliation":[{"name":"Cardiovascular Epidemiology and Genetics Research Lab, Cyprus International Institute for Environmental and Public Health, Cyprus University of Technology, Limassol 3036, Cyprus"},{"name":"Respiratory Physiology Laboratory, Medical School, University of Cyprus, Nicosia 1678, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kousios","sequence":"additional","affiliation":[{"name":"Cardiovascular Epidemiology and Genetics Research Lab, Cyprus International Institute for Environmental and Public Health, Cyprus University of Technology, Limassol 3036, Cyprus"},{"name":"West London Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London W12 0HS, UK"},{"name":"Centre for Inflammatory Disease, Imperial College London, London W12 0HS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrie","family":"Panayiotou","sequence":"additional","affiliation":[{"name":"Cardiovascular Epidemiology and Genetics Research Lab, Cyprus International Institute for Environmental and Public Health, Cyprus University of Technology, Limassol 3036, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/AITC201506020","article-title":"Chronic kidney disease","volume":"162","author":"Drawz","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O\u2019Callaghan, C.A., Lasserson, D.S., and Hobbs, F.D.R. (2016). Global prevalence of chronic kidney disease\u2014A systematic review and meta-analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158765"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am. J. Kidney Dis."},{"key":"ref_4","first-page":"CD009580","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","volume":"2015","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","article-title":"Lipid management in patients with chronic kidney disease","volume":"14","author":"Ferro","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"The ACCORD Study Group, Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, J.R., Leiter, L.A., Linz, P., Friede-Wald, W.T., Buse, J.B., and Gerstein, H.C. (2010). Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N. Engl. J. Med., 362, 1563\u20131574.","DOI":"10.1056\/NEJMoa1001282"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: A systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.amjcard.2012.06.050","article-title":"Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia","volume":"110","author":"Guo","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., G\u00f8tzsche, P.C., Ioannidis, J.P.A., Clarke, M., Devereaux, P.J., Kleijnen, J., and Moher, D. (2009). The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Med., 6.","DOI":"10.2427\/5768"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kousios, A., Hadjivasilis, A., Kouis, P., and Panayiotou, A. (2020). The Effect of Fibrates on Kidney Function and Chronic Kidney Disease Progression: Protocol for a Systematic Review, Research Square.","DOI":"10.21203\/rs.3.rs-104160\/v1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.17219\/acem\/94161","article-title":"Effect of fenofibrate on serum nitric oxide levels in patients with hypertriglyceridemia","volume":"28","author":"Esenboga","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17166","DOI":"10.1038\/s41598-019-53753-7","article-title":"A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury","volume":"9","author":"Cirnigliaro","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.5551\/jat.45799","article-title":"Bezafibrate ameliorates arterial stiffness assessed by cardio-ankle vascular index in hypertriglyceridemic patients with type 2 diabetes mellitus","volume":"26","author":"Yamaguchi","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.5551\/jat.44412","article-title":"Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: A multicenter, placebo-controlled, double-blind, randomized trial","volume":"25","author":"Arai","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e009866","DOI":"10.1161\/JAHA.118.009866","article-title":"Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME-2 Trial","volume":"7","author":"Pinchbeck","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1194\/jlr.M076901","article-title":"Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial","volume":"58","author":"Koopal","year":"2017","journal-title":"J. Lipid Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/1755-5922.12148","article-title":"New Fixed-Dose Combinations of Fenofibrate\/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies","volume":"33","author":"Foucher","year":"2015","journal-title":"Cardiovasc. Ther."},{"key":"ref_21","first-page":"136","article-title":"No effect of switching to high-dose rosuvastatin, add-on nicotinic acid, or addon fenofibrate on serum vitamin D levels in patients with mixed dyslipidemia","volume":"19","author":"Makariou","year":"2015","journal-title":"Hippokratia"},{"key":"ref_22","first-page":"421","article-title":"Increased Rosuvastatin Dose versus Concomitant Fenofibrate and Rosuvastatin Therapy to Achieve Lipid Goal in Patients with Diabetes or Atherosclerosis with Metabolic Syndrome","volume":"29","author":"Chen","year":"2013","journal-title":"Acta Cardiol. Sin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1476-511X-12-133","article-title":"The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome","volume":"12","author":"Li","year":"2013","journal-title":"Lipids Health Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.clinthera.2013.06.013","article-title":"A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease","volume":"35","author":"Weinstein","year":"2013","journal-title":"Clin. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2011.12.042","article-title":"Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia","volume":"221","author":"Lee","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1463-1326.2010.01229.x","article-title":"Fenofibrate concomitantly decreases serum proprotein convertase subtilisin\/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients","volume":"12","author":"Chan","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1185\/03007990903073159","article-title":"Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients","volume":"25","author":"Derosa","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ahj.2008.08.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study","volume":"157","author":"Mohiuddin","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2008.09.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study","volume":"204","author":"Jones","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.ajkd.2008.01.014","article-title":"Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People","volume":"51","author":"Ansquer","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.atherosclerosis.2006.11.028","article-title":"Effect of rosuvastatin 5-20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia","volume":"194","author":"Saito","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.metabol.2005.03.010","article-title":"Targeting vascular risk in patients with metabolic syndrome but without diabetes","volume":"54","author":"Athyros","year":"2005","journal-title":"Metabolism"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/S0149-2918(02)80064-9","article-title":"Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: A randomized, double-blind, placebo-controlled, multicenter, crossover study","volume":"24","author":"Sasaki","year":"2002","journal-title":"Clin Ther."},{"key":"ref_35","first-page":"140","article-title":"A randomized placebo-controlled double-blind trial of lipid lowering strategies in patients with renal insufficiency: Diet modification with or without fenofibrate","volume":"53","author":"Levin","year":"2000","journal-title":"Clin. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000189551","article-title":"Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: A controlled study in human chronic renal disease","volume":"75","author":"Samuelsson","year":"1997","journal-title":"Nephron"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000189120","article-title":"Renal function changes in diabetic nephropathy induced by bezafibrate","volume":"73","author":"Bruce","year":"1996","journal-title":"Nephron"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/0002-9149(92)90463-9","article-title":"Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients","volume":"70","author":"Barbir","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2337\/diacare.13.8.855","article-title":"Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM","volume":"13","author":"Jones","year":"1990","journal-title":"Diabetes Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1016\/j.clinthera.2009.12.007","article-title":"Efficacy and tolerability of atorvastatin\/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study","volume":"31","author":"Davidson","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ki.2014.236","article-title":"The potential for renoprotection with incretin-based drugs","volume":"86","author":"Tanaka","year":"2014","journal-title":"Kidney Int."},{"key":"ref_42","first-page":"CD009753","article-title":"Fibrates for primary prevention of cardiovascular disease events","volume":"11","author":"Jakob","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2215\/CJN.10640918","article-title":"Rate of correction of hypernatremia and health outcomes in critically ill patients","volume":"14","author":"Chauhan","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_44","first-page":"39","article-title":"Deterioration in renal function associated with fibrate therapy","volume":"55","author":"Lipscombe","year":"2001","journal-title":"Clin Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/nep.13764","article-title":"Alport syndrome: Proteomic analysis identifies early molecular pathway alterations in Col4a3 knock out mice","volume":"25","author":"Nicolaou","year":"2020","journal-title":"Nephrology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102046","DOI":"10.1016\/j.isci.2021.102046","article-title":"Acute Kidney Injury Leading to CKD is Associated with a Persistence of Metabolic Dysfunction and Hypertriglyceridemia","volume":"24","author":"Harzandi","year":"2021","journal-title":"iScience"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/sj.ki.5000209","article-title":"PPAR\u03b1 agonist fenofibrate improves diabetic nephropathy in db\/db mic","volume":"69","author":"Park","year":"2006","journal-title":"Kidney Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/ndt\/gfr613","article-title":"High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPAR\u03b1-FoxO3a-PGC-1\u03b1 pathway","volume":"27","author":"Chung","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/dc11-1109","article-title":"Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: The FIELD study","volume":"35","author":"Ting","year":"2012","journal-title":"Diabetes Care."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","article-title":"Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency","volume":"66","author":"Tonelli","year":"2004","journal-title":"Kidney Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/768\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:11:44Z","timestamp":1760134304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jcm11030768"],"URL":"https:\/\/doi.org\/10.3390\/jcm11030768","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]}}}